Calytrix Bio Agrees to Be Acquired by Lilly
Calytrix Bio said it entered an agreement to be acquired by Lilly. Its preclinical program targets essential thrombocythemia and myelofibrosis.
Calytrix Bio said it entered an agreement to be acquired by Lilly. Its preclinical program targets essential thrombocythemia and myelofibrosis.